Alberto dos Santos de Lemos

Prof. Alberto dos Santos de Lemos

Laboratório de Pesquisa em Imunização e Vigilância em Saúde, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BGBeatriz Grinsztejn
Beatriz Grinsztejn
PLPaula M. Luz
Paula M. Luz
APAntonio G. Pacheco
Antonio G. Pacheco
DSDesiree V. G. Santos
Desiree V. G. Santos
LVLuciane Velasque
Luciane Velasque
VVValdilea G. Veloso
Valdilea G. Veloso
Introduction We describe temporal trends in the mortality rates and factors associated with AIDS and non-AIDS related mortality at the Evandro Chagas Clinical Research Institute (IPEC), Oswaldo Cruz Foundation (FIOCRUZ). Methods Adult patients enrolling from 1986 through 2009 with a minimum follow up of 60 days were included. Vital status was exhaustively checked using patients’ medical charts, through active contact with individuals and family members and by linkage with the Rio de Janeiro Mortality database using a previously validated algorithm. The CoDe protocol was used to establish the cause of death. Extended Cox proportional hazards models were used for multivariate modeling. Results A total of 3530 individuals met the inclusion criteria, out of which 868 (24.6%) deceased; median follow up per patient was 3.9 years (interquartile range 1.7–9.2 years). The dramatic decrease in the overall mortality rates was driven by AIDS-related causes that decreased from 9.19 deaths/100PYs n 1986–1991 to 1.35/100PYs in 2007–2009. Non-AIDS related mortality rates remained stable overtime, at around 1 death/100PYs. Immunodeficiency significantly increased the hazard of both AIDS-related and non-AIDS-related causes of death, while HAART use was strongly associated with a lower hazard of death from either cause. Conclusions Our results confirm the remarkable decrease in AIDS-related mortality as the HIV epidemic evolved and alerts to the conditions not traditionally related to HIV/AIDS which are now becoming more frequent, needing careful monitoring.

1 September 2016 in Transplantation Proceedings
Verified
Journal Article
Closed access
LGL.F.A. Guimarães
L.F.A. Guimarães
MHM. Halpern
M. Halpern
ALAlberto dos Santos de Lemos
Alberto dos Santos de Lemos
EGE.F. de Gouvêa
E.F. de Gouvêa
RGR.T. Gonçalves
R.T. Gonçalves
GSG. Santoro-Lopes
G. Santoro-Lopes

1 July 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
EAE.B. Aguiar
E.B. Aguiar
LML.C. Maciel
L.C. Maciel
MHM. Halpern
M. Halpern
ALAlberto dos Santos de Lemos
Alberto dos Santos de Lemos
AFA.L.P. Ferreira
A.L.P. Ferreira
GSG. Santoro-Lopes
G. Santoro-Lopes

1 December 2013 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ALAlberto dos Santos de Lemos
Alberto dos Santos de Lemos
MVM. A. M. S. Vieira
M. A. M. S. Vieira
MHM. Halpern
M. Halpern
RQR. G. Quaresma
R. G. Quaresma
ABA. C. Borchardt
A. C. Borchardt
GSG. Santoro-Lopes
G. Santoro-Lopes
This retrospective cohort study assessed the results of the implementation of preventive recommendations for tuberculosis (TB) among renal transplant recipients in an endemic area (Rio de Janeiro, Brazil). Subjects were defined as at high risk for TB if they had latent tuberculosis infection (LTBI), reported recent close contact with individuals with TB or received a graft from a donor with LTBI. A 6-month course of isoniazid preventive therapy (IPT) was targeted to high-risk subjects. The study end point was TB confirmed by culture. Altogether, 535 patients were included. Median follow-up was 59 months. The overall cumulative incidence of TB was 2.1% while among the 274 patients in whom the preventive protocol was fully implemented, the incidence was only 0.7%. The incidence of TB among 75 high-risk recipients not treated with isoniazid (7%) was significantly higher than that observed in 209 untreated low-risk patients (1%, p = 0.006) and in 65 high-risk subjects that received IPT (no case, p = 0.03). In conclusion, the implementation of preventive recommendations for TB in an endemic area allowed the appropriate discrimination between high- and low-risk renal transplant recipients and was associated with long-term reduction in the incidence of this complication among high-risk subjects.

1 October 2012 in Clinical Immunology
Verified
Journal Article
Closed access
RARegis M. Andrade
Regis M. Andrade
JHJoana Hygino
Joana Hygino
TKTaissa M. Kasahara
Taissa M. Kasahara
MVMorgana M. Vieira
Morgana M. Vieira
LXLuciana F. Xavier
Luciana F. Xavier
CBCleonice A.M. Bento
Cleonice A.M. Bento

25 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMarilia Santini-Oliveira
Marilia Santini-Oliveira
LCLuiz A. B. Camacho
Luiz A. B. Camacho
TSThiago Moreno Lopes e Souza
Thiago Moreno Lopes e Souza
PLPaula M. Luz
Paula M. Luz
MVMauricio T. L. Vasconcellos
Mauricio T. L. Vasconcellos
BGBeatriz Grinsztejn
Beatriz Grinsztejn
Since human immunodeficiency virus (HIV)-infected individuals are at increased risk of severe disease from pandemic influenza A (H1N1pdm09), vaccination was recommended as a prevention strategy. The aim of the present study was to evaluate the safety, immunogenicity and persistence of the immune response after vaccination against pandemic influenza A (H1N1pdm09) with an adjuvanted vaccine in human immunodeficiency virus (HIV)-infected adults using two single and two double doses. Open label, randomized trial to evaluate the immune response following H1N1pdm09 vaccination in HIV-infected participants compared to HIV-negative controls (NCT01155037). HIV-infected participants were randomized to receive 2 single (3.75 µg hemagglutinin) or 2 double (7.5 µg hemagglutinin) doses of the vaccine, 21 days apart. Controls received one dose of the vaccine. The primary endpoint was seroconversion as measured by hemagglutination inhibition assay. Two hundred fifty six HIV-infected participants (129 and 127 randomized to single and double doses, respectively) and 71 HIV-negative controls were enrolled. Among HIV-infected participants, seroconversion increased from 46.7% and 51.7% after the first dose to 77.2% and 83.8% after the second dose of the vaccine using single and double doses, respectively. Participants aged >40 years showed higher seroconversion compared to younger participants. Seroconversion among HIV-infected women and those with nadir CD440 years or with nadir CD4<200 cells/mm3, to achieve antibody levels that are both higher and more sustained. ClinicalTrials.gov NCT01155037